Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,352 result(s) found. Displaying page 961 of 2,218.
    «« First « Previous 957  958  959  960  961  962  963  964  965  Next» Last»»
    EudraCT Number: 2004-000727-15 Sponsor Protocol Number: 9238IL/0048 Start Date*: 2004-12-03
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Double Blind, Multicenter Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX™) vs. Exemestane (AROMASIN™) in Postmenopausal Women with Hormone Receptor Positive A...
    Medical condition: Hormone receptor positive breast cancer with disease progression after prior non-steroidal aromatase inhibitor (AI) therapy
    Disease:
    Population Age: Elderly Gender: Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2004-000290-58 Sponsor Protocol Number: SP755 Start Date*: Information not available in EudraCT
    Sponsor Name:SCHWARZ BIOSCIENCES GmbH
    Full Title: Estudio multicéntrico, doble ciego, aleatorizado, controlado con placebo, en grupos paralelos, para investigar la eficacia y la seguridad de SPM927 (200 mg y 400 mg/día)como tratamiento complementa...
    Medical condition: Partial seizures with or without secondary generalization
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2004-001181-41 Sponsor Protocol Number: CN138-125 Start Date*: 2005-01-10
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Prospective, Multicenter, Open-Label Study of Aripiprazole in the Management of Patients with Schizophrenia in General Psychiatric Practices
    Medical condition: Schizophrenia or schizoaffective disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) HU (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2004-003809-25 Sponsor Protocol Number: L-9134 Start Date*: 2004-12-20
    Sponsor Name:Sanofi-Synthelabo Co. Ltd.
    Full Title: Comparison of the efficacy and tolerability of drotaverine 80 mg or ibuprofen 400 mg administered alone with their combination for the treatment of primary and secondary dysmenorrhea
    Medical condition: A NO-SPA és az ibuprofen kombinációja elfogadott és Magyarországon gyakran használták a nőgyógyászati gyakorlatban sok évvel ezelőtt. A kombináció használatával kapcsolatos súlyos mellékhatásról ne...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001646-32 Sponsor Protocol Number: TTstudy-04 Start Date*: 2004-11-18
    Sponsor Name:Dr. DANIEL PODZAMCZER PALTER
    Full Title: ESTUDIO PILOTO PARA EVALUAR LA EFICACIA Y TOLERANCIA DE LA COMBINACION DE TRIZIVIR Y TENOFOVIR EN PACIENTES INFECTADOS POR EL VIH, SIN TRATAMENTO ANTIRRETROVIRAL PREVIO (NAÏVES)
    Medical condition: INFECCION POR VIH.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002395-41 Sponsor Protocol Number: 309100 Start Date*: 2004-12-03
    Sponsor Name:Schering AG
    Full Title: Phase II study of MS-275, a histone deacetylase inhibitor, comparing 2 dosage schedules in patients with metastatic melanoma
    Medical condition: Metastatic malignant melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-003700-38 Sponsor Protocol Number: 03/169-SENIOR Start Date*: 2004-11-11
    Sponsor Name:Profil Institut fuer Stoffwechselforschung GmbH
    Full Title: Einfluß einer supplementären Therapie mit postprandial injiziertem Insulin Lispro (Huma-log®) auf diabetesbezogene Komplikationen und Lebensqualität bei geriatrischen Patienten mit Typ 2 Diabetes
    Medical condition: Diabetes
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-002511-83 Sponsor Protocol Number: TTP889-201 Start Date*: 2005-01-03
    Sponsor Name:TransTech Pharma
    Full Title: A Multi-Center, Placebo-Controlled Evaluation of the Safety and Efficacy of Three Weeks Extended VTE Prophylaxis with Daily Oral Doses of TTP889 After One Week of Standard Prophylactic Treatment Fo...
    Medical condition: Antithrombotic in patients at risk for venous thromboembolism
    Disease: Version SOC Term Classification Code Term Level
    7 10047249 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) CZ (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-003981-13 Sponsor Protocol Number: CL3-20098-041 Start Date*: 2004-12-16
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: A study to determine the maintenance of efficacy of agomelatine (25 mg to 50 mg) to prevent relapse in out-patients with Major Depressive Disorder. A 8 to 10 weeks open period treatment with agome...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    3.3 10025453 P.T.
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000953-46 Sponsor Protocol Number: SOV301 Start Date*: 2004-10-13
    Sponsor Name:Amersham plc
    Full Title: A Multicentre, Phase 3, Open-Label, Controlled Study Evaluating the Efficacy and Safety of 0.1 mmol/kg Omniscan (Gadodiamide Injection) in Magnetic Resonance Angiography (MRA) of the Renal Arteries
    Medical condition: Renal artery stenosis (RAS) is implicated as the underlying cause in 1% to 5% of patients with hypertension and 5% to 15% of patients with end-stage renal disease entering dialysis programs each ye...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005163-29 Sponsor Protocol Number: 05BFCH/Co04 Start Date*: 2006-03-09
    Sponsor Name:IBSA (Institut Biochimique SA)
    Full Title: “A multicentre, comparative, randomised, double-blind clinical trial on the equivalence of the efficacy and the safety of CHONDROSULF® 1200 mg, oral gel in sachet, once daily, versus CHONDROSULF® 4...
    Medical condition: Knee osteoarthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2005-000449-12 Sponsor Protocol Number: 104480 Start Date*: 2005-08-09
    Sponsor Name:GlaxoSmithKline
    Full Title: A phase II, double-blind, randomized, placebo controlled study to compare the immunogenicity, reactogenicity and safety of two different formulations of GlaxoSmithKline (GSK) Biologicals’ live atte...
    Medical condition: Immunization of healthy infants against HRV disease/illness.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2005-004955-36 Sponsor Protocol Number: CHR-2797-002 Start Date*: 2006-03-27
    Sponsor Name:Chroma Therapeutics Ltd.
    Full Title: A Phase I-II Study to Evaluate the Safety, Tolerability and Anti-Disease Activity of the Aminopeptidase Inhibitor, CHR-2797, in Elderly and/or Treatment Refractory Patients with Acute Myeloid Leuka...
    Medical condition: Treatment refractory Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS) or Multiple Myeloma (MM)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000880 Acute myeloid leukaemia LLT
    9.1 10028535 Myelodysplastic syndrome unclassifiable LLT
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-003853-13 Sponsor Protocol Number: HPEPA-01 Start Date*: 2005-01-13
    Sponsor Name:Hela Pharma AB
    Full Title: Placebo controlled, randomised, double-blind, multicentre study of PlusEPA (a PUFA, Polyunsaturated Fatty Acids, supplement) as treatment for ADHD (combined type) with co-morbidity in Swedish child...
    Medical condition: ADHD (combined type) and co-morbidity in children
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006199-39 Sponsor Protocol Number: 310523 Start Date*: 2007-07-05
    Sponsor Name:Bayer AB, Bayer Schering Pharma
    Full Title: A double-blind, randomized, multi-center study to investigate the endometrial safety of a continuous, combined, oral estrogen/progestin preparation (0.5 mg 17b-estradiol [E2] / 0.25 mg drospirenone...
    Medical condition: Women suffering from postmenopausal symptoms
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050903 Postmenopausal symptoms LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002887-41 Sponsor Protocol Number: OV-W05 Start Date*: 2004-12-01
    Sponsor Name:OmniVision GmbH
    Full Title: Randomisierte, kontrollierte, für den Prüfer verblindete klinische Prüfung (Pilotstudie) zur Untersuchung der Wirksamkeit von Spersadex® Augentropfen im Vergleich zu Isopto®-Dex Augentropfen bei Pa...
    Medical condition: Nicht-infektiöse Conjunctivitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-005123-18 Sponsor Protocol Number: 104020 Start Date*: 2005-04-15
    Sponsor Name:GlaxoSmithKline
    Full Title: A phase III, partially blind, randomised, primary vaccination study to assess the immunogenicity and safety of three different lots of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mum...
    Medical condition: Active immunization of healthy children during their second year of life against measles, mumps, rubella and varicella diseases.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004225-10 Sponsor Protocol Number: 3001081 Start Date*: 2005-03-07
    Sponsor Name:Orion Pharma
    Full Title: Effects of peroral levosimendan in the prevention of further hospitalisations in patients with chronic heart failure. A randomised, double-blind, placebo-controlled, multi-centre, parallel-group study
    Medical condition: Cardiac Failure
    Disease: Version SOC Term Classification Code Term Level
    7.1 10007554 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) LT (Completed) LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000408-41 Sponsor Protocol Number: RNA003142-302 Start Date*: 2004-10-07
    Sponsor Name:Ribapharm, Inc.
    Full Title: RANDOMIZED, DOUBLE–BLIND, MULTICENTER STUDY TO COMPARE THE SAFETY AND EFFICACY OF VIRAMIDINE TO RIBAVIRIN IN TREATMENT–NAïVE PATIENTS WITH CHRONIC HEPATITIS C
    Medical condition: Chronic Hepatitis C Viral Infection
    Disease: Version SOC Term Classification Code Term Level
    5.1 10008912 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-003778-27 Sponsor Protocol Number: 0881A8-205 Start Date*: 2005-03-30
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical resaearch and Development
    Full Title: A Randomized Double-Blind Placebo Controlled Trial Evaluating the Safety and Efficacy of Etanercept 25 mg Twice Weekly in Subjects with Moderate to Severe Persistent Asthma
    Medical condition: Moderate to severe asthmatics
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 957  958  959  960  961  962  963  964  965  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Aug 02 10:12:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA